The Gray Market Passed $100 Million On-Chain. Spending on Testing Fell to $8 a Buyer

The numbers, from the report itself

Cryptocurrency reaching gray-market peptide vendors rose from $12 million in the last quarter of 2025 to $32 million in the first quarter of 2026, a 159% increase, after sitting at roughly $1 million a quarter through 2024. Chainalysis counted six consecutive quarters of growth and put the second quarter of 2026 on pace for $39 million, which crosses a $100 million annual run rate. Monthly inflows went from about $200,000 before 2025 to $9.9 million, with recent peaks above $10 million.

One caution about the headline figure, because the coverage is inconsistent. Several outlets report a 700% rise and attribute it to this report. The report itself states 159%, quarter over quarter; a 700% figure is a year-over-year comparison against the much smaller 2024 base. Both can describe the same data, but they are not the same claim, and it is worth knowing which one a story is quoting.

A second caution is the firm's own. These are crypto flows. Vendors that take cards or bank transfers are not in the count, so the figure is a floor for one payment rail rather than a measure of the market.

The finding that matters if you are buying

Deeper in the report is a measurement nobody else led with. In the market's earlier phase, buyers routinely paid to have what arrived from overseas independently tested, and the on-chain record shows that spending. As the market went mainstream through late 2025, that spending per buyer fell by an estimated 88%, to roughly $8 a buyer. The testing laboratory most used in this space is busier than ever in absolute terms, with monthly inflows up from about $187,000 to about $502,000, but it is being paid by a far smaller share of a far larger market.

What replaced independent testing is the vendor-supplied certificate. The report makes the limitation explicit, and it is the one this site has been making for a year: a purity certificate reports purity. It frequently does not report sterility. The report describes a batch of retatrutide that arrived with a passing mass and purity certificate, and failed when a buyer paid to have it tested for sterility independently.

That distinction is not academic for an injected product. A vial can be exactly the compound the label claims, at the purity the certificate states, and still carry bacteria or endotoxin that purity testing was never designed to look for.

Where this leaves a reader

Our COA decoder exists for this gap: paste a certificate and it says what the document does and does not establish, including whether sterility was tested at all. Our verification guide covers how to read one and what a credible one looks like. Neither can tell you what is in a particular vial, which is the limit of any document-reading exercise, and is why we are building a database of published independent test results rather than asking anyone to trust a certificate supplied by the party selling the product.

The report also traces some vendors to Chinese chemical manufacturers that previously supplied fentanyl and amphetamine precursors and pivoted to peptides, one of them continuing to use the same contact number. We do not name sellers on this site in either direction, so those names are in the report and not here. The relevant point for a buyer is structural: the report's own account is of suppliers choosing peptides because the legal risk is lower and the retail margin is higher, which says nothing about what is in the vial, and is not a reason to trust the paperwork that comes with it.

Related on Grey Peptides